Genetic and Environmental Risk Factors in African American and Caucasian Healthy Men and in Patients With Prostate Cancer
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate
Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
MRI for Assessing Prostate Cancer Response
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer
Transrectal Ultrasound Robot-Assisted Prostate Biopsy
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombinatio
Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repai
Clinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI)
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer
Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN)
Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA
Decision Navigation for Advanced Prostate Cancer Treatment Options Using mHealth
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
Muscadine Plus (MPX) In Men With Prostate Cancer
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer
Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer
Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer
Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer
RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers
EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression
Augmented BLAdder NecK rEconstruction Trial for Improved Urinary Function After Radical Prostatectomy